Replimune group, inc. (REPL)
Income statement / Quarterly
Dec'19Sep'19Jun'19Mar'19Dec'18Sep'18Jun'18Mar'18Dec'17Sep'17Jun'17
Operating expenses:
Research and development

11,948

8,168

7,457

5,418

7,857

4,962

3,936

4,503

3,573

3,149

2,291

General and administrative

4,716

4,074

3,450

2,408

2,280

2,142

1,943

2,562

1,159

1,107

885

Total operating expenses

16,664

12,242

10,907

7,826

10,137

7,104

5,879

7,065

4,732

4,256

3,176

Loss from operations

-16,664

-12,242

-10,907

-7,826

-10,137

-7,104

-5,879

-7,065

-4,732

-4,256

-3,176

Other income (expense):
Research and development incentives

951

620

621

590

1,577

-77

438

525

639

636

467

Investment income

550

567

687

812

882

664

227

-

-

-

-

Interest expense

834

195

-

-

-

-

-

-

-

-

-

Interest income

-

-

-

-

-

-

-

-

32

10

30

Change in fair value of warrant liability

-

-

-

0

0

2

5,450

-

387

578

-

Other income (expense)

-192

111

91

-232

5

58

620

-805

94

-472

-873

Total other income (expense), net

475

1,103

1,399

1,170

2,464

643

-4,165

-71

378

-404

-376

Net loss

-

-

-9,508

-

-

-

-10,044

-7,136

-4,354

-4,660

-3,552

Net loss attributable to common stockholders

-16,189

-11,139

-9,508

-6,656

-7,673

-6,461

-10,044

-7,136

-4,354

-4,660

-3,552

Net loss per share attributable to common shareholders, basic and diluted (in dollars per share)

-0.46

-0.35

-0.30

1.19

-0.24

-0.26

-2.02

-1.44

-0.87

-0.94

-0.71

Weighted average common shares outstanding-basic and diluted (in shares)

34,877

31,675

31,661

31,660

31,577

24,574

4,981

4,981

4,981

4,978

4,973